 Anacet Bio announcing that the FDA has granted FastTrack designation to a potential treatment for a certain type of cancer, which is called ADI-270. And this week, Figma will temporarily disable its new AI feature due to growing controversy. The San Francisco-based company is accused of heavily training its MakeDesign tool on existing apps.